

Original Research**Psychobiologic Correlates of Stress in Individuals With COPD**

Trisha M. Parekh, DO, MSPH¹ Rekha Ramachandran, MS² Young-il Kim, PhD² Zahra Haider³
Darlene Bhavnani, PhD, MPH⁴ J. Michael Wells, MD, MSPH^{5,6,7} Elizabeth Matsui, MD⁴ Mark
T. Dransfield, MD^{5,6,7}

¹Division of Pulmonary and Critical Care, University of Texas at Austin, Austin, Texas, United States

²Department of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States

³Undergraduate Program, University of Texas at Austin, Austin, Texas, United States

⁴Department of Population Health, University of Texas at Austin, Austin, Texas, United States

⁵Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States

⁶Heersink School of Medicine Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama, United States

⁷Section for Pulmonary and Critical Care Medicine, Birmingham VA Healthcare System, Birmingham, Alabama, United States

Address correspondence to:

Trisha M. Parekh, DO, MSPH
University of Texas at Austin Dell Medical School
Division of Pulmonary and Critical Care
1601 Trinity Street Building A
Austin, TX 78712
Email: trisha.parekh@austin.utexas.edu

Running Head: Nail Cortisol as a Marker of Stress in COPD

Keywords: COPD; psychological stress; nail cortisol

Abbreviations: COPD – chronic obstructive pulmonary disease; HPA - hypothalamic-pituitary-adrenal; SD – standard deviation; UAB – University of Alabama; CRP - C-reactive protein ; IL-1b - interleukin – 1 beta ; IL-6 - interleukin-6 ; SDH – social determinants of health; CAT – COPD Assessment Test ; IQR – interquartile range ; ICS – inhaled corticosteroids

Funding Support: None

Date of Acceptance: May 7, 2025 | ***Published Online:*** May 8, 2025

Citation: Parekh TM, Ramachandran R, Kim Y, et al. Psychobiologic correlates of stress in individuals with COPD. *Chronic Obstr Pulm Dis*. 2025; Published online May 8, 2025.

<https://doi.org/10.15326/jcopdf.2024.0578>

This article has an online supplement.

ABSTRACT

RATIONALE: Psychological stress is elevated in individuals with chronic medical conditions, including those with chronic obstructive pulmonary disease (COPD). Nail cortisol may have utility as a marker for testing the biologic effects of stress reduction interventions. The aim of this pilot study is to explore the use of nail cortisol as a marker of chronic psychological stress in individuals with COPD.

METHODS: Pearson's correlation was used to test if nail cortisol was correlated with perceived stress, serum cortisol, or inflammatory biomarkers. Multivariable linear regression model was used to evaluate the association between perceived stress and nail cortisol. Stepwise logistic regression modeling was used to determine associations of psychobiologic measures of stress with demographic, clinical, and psychological variables.

RESULTS: Fifty participants were included in the study. The mean (SD) perceived stress score was 12 (+/-6) and mean (SD) nail cortisol level was 0.05 (+/-0.09) nmol/g. Nail cortisol was not correlated with perceived stress, serum cortisol, or inflammatory markers. There was no association between nail cortisol and perceived stress after controlling for confounders. Suboptimal health status and grit score were associated with perceived stress. Higher levels of serum fibrinogen were associated with higher levels of serum cortisol. Experiencing three or more negative lifetime events was associated with a decrease in nail cortisol.

CONCLUSIONS: We found no correlation between nail cortisol and levels of perceived stress, serum cortisol, or inflammatory biomarkers and there were no similar associations of variables across psychobiologic measures of stress.

Pre-proof

INTRODUCTION

There is mounting evidence that individuals with diseases of chronic inflammation, including chronic obstructive pulmonary disease (COPD), coronary artery disease, asthma, and auto-immune diseases, are more susceptible to the deleterious effects of chronic stress.^{1,2} Under states of chronic stress, cortisol, the primary neuroendocrine stress hormone, loses its ability to regulate inflammation. Inflammatory cytokines, including tumor necrosis factor-1, interleukin-6, and interleukin-1 beta, are activated by the disruption of the hypothalamic-pituitary-adrenal (HPA) axis and by stimulation of the sympathetic nervous system. A prolonged increase in cortisol increases glucocorticoid resistance leading to unregulated inflammation, suppressed cellular immunity, and heightened vulnerability to respiratory viruses.^{3,4} Our prior work has found an association between increased levels of stress and risk of severe COPD exacerbation.⁵ While the benefit of stress reduction on exacerbation risk remains unknown, stress reduction may be a key non-pharmacologic therapy for improving quality of life in patients with chronic diseases, including COPD. In addition, the concept of grit, defined as “passion and perseverance towards long-term goals” has been studied in the positive psychology field and may have a significant impact in mitigating the negative effects of stress on our health.⁶ Grit has use been associated with lower levels of stress and burnout in other populations yet has not been studied in COPD^{7,8}.

Psychological intervention studies frequently use serum or salivary cortisol and other inflammatory markers as surrogate biologic outcomes for the effectiveness of their stress reduction interventions.^{9,10} However, the use of serum or salivary cortisol as a marker of stress in COPD encounters some specific limitations. First, tobacco use can acutely increase serum cortisol, which may overestimate levels of “stress.”¹¹ Second, treatment of acute exacerbations

of COPD with steroids can suppress cortisol production, which may take up to 14 days after treatment to recover.^{12,13} Prior research in cancer patients has found that measurement of cortisol levels from nail clippings, a novel measure of physiologic stress, provides an assessment of chronic cortisol accumulation, approximately 3-5 months prior.¹⁴ A case-control study of 162 men in a Japan who experienced acute coronary syndrome has also tied levels of nail cortisol with a 2-fold increase in the risk of acute coronary syndrome.¹⁵ The utility of nail cortisol levels in the measurement of chronic stress and the association with clinical outcomes in individuals with COPD is unknown but may avoid the limitations that are present with salivary and serum testing, including their diurnal pattern of release and intra- and inter-day variations. While cortisol may be measured from hair samples, many patients dislike hair samples for cultural reasons or for lack of hair, which is common in the elderly COPD population, presenting an additional advantage to the use of nail clippings.

To determine the utility of nail cortisol as a biologic measure of chronic stress in COPD, we evaluated the relationship between nail cortisol and perceived stress in individuals living with COPD. We also examined associations of psychobiologic measures of stress (perceived stress, serum cortisol, nail cortisol) with demographic, clinical, and psychological variables, including grit, in COPD to determine if there were similar associations across measures of stress. We hypothesized that nail cortisol would be a reliable biologic measure of perceived stress in COPD and that associations of nail cortisol with demographic, clinical, and psychological variables would be similar to other measures of stress (perceived stress and serum cortisol).

METHODS

Study Design

This study is a cross-sectional study of individuals with COPD conducted at the University of Alabama at Birmingham (UAB). The UAB Institutional Review Board approved the study.

Written consent was obtained from all participants.

Participant Selection and Setting

Participants were recruited from the UAB Lung Health Center and UAB pulmonary clinics from November 2019 – May 2022. Individuals were included in the study if they had a smoking history of ≥ 10 pack years (either current or former smoker) with spirometry meeting COPD criteria (FEV1/FVC ratio < 0.7)¹⁶, were able to read and write independently, and were able to speak English. Exclusion criteria included major cognitive impairment, diagnosis of interstitial lung disease, daily use of oral corticosteroids, or if they were treated for a COPD exacerbation in the 4 weeks prior to the research visit.

Measurements

This study involved the collection of primary data using surveys, blood samples, and nail samples which were collected at a single time point. Our primary psychobiologic measures of stress included 1) nail cortisol, 2) serum cortisol, and 3) perceived stress.

Nail samples: Participants were instructed to have 2 weeks of fingernail growth prior to the baseline visit. They had 10 fingernails clipped during the baseline assessment and stored in labeled plastic bags at room temperature. Nail cortisol levels were processed at the Bio-Analytical Redox Biology (BARB) Core lab at UAB using a slightly modified procedure as described by Warnock and Meyer et al.^{17,18} Nail clippings were washed twice with 2 ml isopropanol and dried overnight. Fifty mg of nail were ground into a powder by 5 mm steel grinding balls, combined with methanol (1 ml per 50 mg of powdered nail), and placed on a rotator for 18 hours to extract the cortisol. Samples were centrifuged and cortisol levels were

measured using enzyme immunoassay kits (ELISA). If samples remained outside of the range for the standard curve after being re-run they were excluded from analysis (n=4). Samples were run in 2 separate batches (n=33, n=23). The inter-assay coefficient of variation was 6.9% for the high standard and 0.8% for the low standard for the first batch and 5.3% for the high standard and 3.7% for the low standard for the second batch.

Blood samples: Cortisol levels were determined by enzyme immunoassay. Serum cortisol was measured from a blood draw before 10 AM and participants were asked to refrain from exercise, caffeine use, tobacco use, alcohol use, and sleep loss prior to a fasting blood draw. Fibrinogen, C-reactive protein (CRP), interleukin – 1 beta (IL-1b), and interleukin-6 (IL-6) were also measured using commercially available ELISA kits.

Surveys: Perceived stress over the prior month was measured using Cohen's Perceived Stress Scale, a 10-item instrument with a score ranging from 0-40 and higher scores indicating higher levels of stress; psychometric properties indicate adequate reliability (Cronbach's Alpha coefficient 0.78)^{20,21,22} Life events were measured from the Life Events Checklist, which assessed total negative and positive life events that occurred over the prior 12 months.^{23,24} For our analysis, we only included total negative life events as we expected the experience of negative events to influence chronic stress. Grit was measured by the Short Grit Scale, an 8-item instrument with scores ranging from 1-5, with higher scores indicating higher levels of grit or resilience.⁶ Depression was measured using the Patient Health Questionnaire – 2, which includes 2 questions about the frequency of anhedonia and depressed mood over the prior 2 weeks. A score of 3 or greater (scale 0-6) indicated major depressive disorder is likely.²⁵ Social determinants of health (SDH) were measured by the Protocol for Responding to & Assessing Patients' Assets, Risks & Experiences (PRAPARE) questionnaire, a 21 question survey assessing

SDH domains including housing, transportation, and financial insecurity.²⁶ Based on answers to this questionnaire, we derived whether an individual experienced financial insecurity. This was defined as being unable to afford either food, utilities, clothing, phone, childcare, medicine, or healthcare. We also determined level of social support from the PRAPARE questionnaire which asks “How often do you see or talk to people that you care about and feel close to (less than once a week, 1-2x a week, 3-5x a week, 5 or more x a week)?” Health status was assessed by the question “In general, how would you rate your health (excellent, very good, good, fair, poor)?” The impact of COPD symptoms over the prior week on quality of life was measured by the COPD Assessment Test (8 item instrument; score range 0-40 with higher scores indicating more symptoms).²⁷ Dyspnea was measured with the Modified Medical Research Council instrument, which measures degree of breathlessness.²⁸ In addition, participants took a comprehensive survey that inquired about medication use, COPD-related symptoms, healthcare utilization for acute exacerbations of COPD over the prior 12 months, comorbidities, and tobacco use.

Statistical Analysis

Descriptive statistics for sociodemographic and clinical characteristics including stress measures of study subjects were tabulated for the total population. Pearson’s correlation was used to estimate the relationship between nail cortisol and perceived stress, serum cortisol, and inflammatory biomarker measurements. We used a multivariable linear regression model to evaluate the association between perceived stress and nail cortisol, controlling for confounders that may affect cortisol levels over time including current tobacco use, use of anxiety or depression medications, and use of antihypertensive medications. Linear and logistic regression models were used to assess the relationship between individual demographic (age, sex, race, financial insecurity), clinical (symptoms as measured by the COPD Assessment Test [CAT],

moderate or severe exacerbations, health status, smoking status, fibrinogen, IL-1B, IL-6, CRP), and psychological (depression [PHQ-2], grit [Short Grit Scale], negative life events [Life Events Checklist]) covariates determined a priori to be important in psychological stress and the following outcomes: levels of perceived stress, serum cortisol, and nail cortisol. For the logistic regression model, median values of perceived stress, serum cortisol, and nail cortisol were used to determine “high” vs. “low” levels of stress. A stepwise logistic regression approach was applied to select the optimal set of predictors while avoiding potential multicollinearity issues among the tested variables, using entry and stay P-values of less than 0.05. Demographic variables were chosen a priori to remain in the model. All statistical analyses were performed using SAS 9.4. Results were determined to be statistically significant when the accompanying statistical test yielded a two-tailed probability of less than 0.05.

RESULTS

Fifty participants had valid nail cortisol data available and were included. **Table 1** displays baseline characteristics of the cohort. The cohort included 42% women and 40% non-white individuals with a mean (SD) age of 65±8. Most individuals were former smokers (52%) and 14% experienced financial insecurity. The cohort had a mean (SD) FEV1 of 50+/-17% predicted and a majority had either moderate or severe airflow obstruction (98%). Approximately 1/5 of the cohort (19%) was on long-term oxygen therapy. In the prior 12 months, 46% of individuals had a moderate exacerbation and 28% had a severe exacerbation (defined as emergency department visit or hospitalization). The cohort had high symptom burden (CAT mean 20) and a high prevalence of acid reflux (50%), anxiety (38%), and depression (36%). The median (IQR) nail cortisol level was 0.016 (0.03) nmol/g, median (IQR)

serum cortisol was 9.1 (5.3) mcg/dl, and the median (IQR) perceived stress level was 12 (9), which is in the lower tertile of the scale's score however similar to normative scores for the general population over 45 years old (45 and over: PSS 11.9-12.6).²¹ **Supplemental Tables 1a-1c** describe baseline characteristics of the cohort based on median (low and high) levels of perceived stress, serum cortisol, and nail cortisol, respectively. Individuals with high perceived stress were more likely to be women, have higher symptom burden, fair or poor health status, higher PHQ-2, more negative life events, and lower levels of grit compared to individuals with lower perceived stress. Individuals with high serum cortisol were more likely to be male, have coronary artery disease and sleep apnea, and have higher fibrinogen and grit levels. Those with high nail cortisol had lower rates of exacerbations (total, moderate, and ED visits) and a higher likelihood of having acid reflux and osteoarthritis.

We found that nail cortisol was not significantly correlated with perceived stress (Pearson's $r = -0.11$; $p=0.4$), serum cortisol (Pearson's $r = 0.04$; $p=0.7$), or any other inflammatory biomarkers (**Table 2, Supplemental Figure 1**). After controlling for current tobacco use, use of anxiety or depression medications, and use of antihypertensive medications, we did not find a significant association between perceived stress and nail cortisol (Beta (standard error) = -0.001 (0.002); $p=0.8$).

Supplemental Table 2 shows the results of univariate linear regression models of perceived stress, serum cortisol, and nail cortisol. Results indicated higher CAT score, higher PHQ2, financial insecurity, and more total negative life events were associated with higher perceived stress levels while higher grit and male sex were associated with lower perceived stress levels. There were no associations in the univariate analyses of covariates with serum cortisol; the direction and strength of nonsignificant associations were not similar compared to

associations with perceived stress or nail cortisol. Nail cortisol had a weak negative association with total negative life events. **Tables 3-5** shows the unadjusted and adjusted odds ratios of covariates predicting perceived stress, serum cortisol, and nail cortisol, respectively. Health status (fair/poor vs. excellent/very good/good) was associated with increased odds of having high perceived stress [OR (95% CI), 15.7 (1.6, 153.6)] while each point higher on the grit score (indicating more grit) was associated with 98% lower odds of having high perceived stress [OR (95% CI), 0.02 (0.002, 0.258)]. Fibrinogen was significantly associated with serum cortisol [OR (95% CI), 1.009 (1.001, 1.017)]. Total number of negative events (3 or more vs 0-2) was significantly negatively associated with nail cortisol [OR, (95% CI), 0.104 (0.017, 0.625)]. There were no similarities in associations between demographic, clinical, and psychological variables and psychobiologic correlates of stress.

DISCUSSION

In this pilot study, we found that nail cortisol was not correlated with perceived stress, serum cortisol, or inflammatory biomarkers and there was no association between nail cortisol and perceived stress in a model controlling for confounders. Moreover, there were no similarities in associations between demographic, clinical, and psychologic variables and various measures of stress. The total number of negative life events was the only significant covariate associated with nail cortisol, however, unexpectedly, there was a negative association such that individuals with a greater number of negative life events had a lower level of nail cortisol. Our study suggests that the relationship between perceived stress and its biologic consequences in COPD is complex and likely influenced by several unmeasured confounders.

Psychological stress in COPD is underrecognized and undertreated. In prior work, we have found that individuals living with COPD sampled from a pulmonary clinic who had high stress levels were more likely to rate their health as “poor” and had higher burden of symptoms based on the COPD Assessment Test scores. This “high stress” group was also twice as likely to have severe exacerbations in the prior 2 years. When accounting for low income, those with high stress had 4-fold increased odds with severe exacerbations of COPD.⁵ The ability to identify and treat patients at risk for unregulated or chronic stress is an integral factor that can lead to improved quality of life and possibly improved clinical outcomes.

Understanding how to measure chronic stress in COPD is the first step in being able to identify patients at risk for its negative downstream effects. Since the seminal papers by Warnock and Meyers et al. were published in 2010,^{17,18} the current literature on nail cortisol as an emerging chronic stress biomarker has evolved with several exploratory studies showing mixed results with regards to correlations with other known measures of stress. While the causal pathway between perceived stress, hypercortisolism, and a subsequent increase in nail cortisol is logical, our results are consistent with other exploratory studies published which did not find a correlation with perceived stress and nail cortisol.^{29,30,31} In a study of 123 middle-aged workers, perceived stress was not associated with nail cortisol levels taken at a single time point. While the cross-sectional study design of this study, similar to ours, may have limited the evaluation of nail cortisol with past perceived stress,²⁹ a longitudinal study of 47 low-income mostly Black (97%) adolescents also found no correlation between perceived stress assessed at baseline and nail cortisol assessed at a 2 month follow up.³¹ The absence of a significant relationship between perceived stress and nail cortisol is similar to findings in studies examining perceived stress and hair cortisol, another biologic measure of chronic stress.³² This may be due

to the inherent limitations of survey-based assessments which can be affected by social desirability, prestige, or central tendency bias. Cross-cultural differences in interpretation of stress may also introduce bias when using survey-based assessments.

While positive associations between experience of stressful life events and elevated nail cortisol levels have been shown in other populations (middle age workers, Serbian refugees),^{29, 33} in our study, we found that more negative life events were associated with lower nail cortisol levels. While surprising, negative associations between stressful life events and nail cortisol have been seen in high-stress populations. A study of Australian Indigenous (n=179) and non-Indigenous (n=66) young adults found that the Indigenous group had a higher number of stressful life events compared to the non-Indigenous group (median 6.0; interquartile range (IQR) 4, 9 vs. 1.0; IQR 0, 2; $p < .001$). In a multivariable regression analysis examining associations with nail cortisol, there was a strong association of Indigenous status and nail cortisol level (geometric mean 1.82; 95% CI: 1.07–3.09, $p = .027$). However, when examining the relationship between stressful events and nail cortisol level by Indigenous status, the study found that Indigenous young adults had a 11% lowering of fingernail cortisol levels for each stressful event (GM = 0.89; 95% CI: 0.84–0.95; $p = .001$) while there was no significant association for non-Indigenous young adults. The authors of this study postulated that Indigenous young adults are under states of severe chronic stress, which may exhaust their stress response leading to a hypoactive state of cortisol production.³⁴ This diminished functionality of the HPA axis leading to hypocortisolism is documented in healthy individuals who experienced traumatic childhood events as well.^{35,36} Similarly, individuals with chronic stress and COPD may live under states of heightened systemic inflammation, both from their underlying lung disease and from heightened stress. Over time, their ability to produce cortisol may be

diminished, which may explain the correlation between increased number of negative life events and lower nail cortisol.

Our study results should be interpreted considering several limitations. First, measurements were taken at a single timepoint, therefore nail cortisol could not be compared to preceding measurements of perceived stress or serum cortisol to determine causality. Cortisol can be deposited into nail beds either by deposition into the nail matrix or by diffusion into the nail bed. Deposition into the nail matrix can reflect cortisol released up to 6 months prior while diffusion into the nail bed can reflect cortisol from 1 week prior.³⁷ The temporal reflection of cortisol release into the nail bed still requires further understanding and has implications for the methodology in future nail studies. Second, our sample size was small, taken from a single academic medical center, and the median perceived stress level was in the lower tertile of the scale, which was near the normative values of perceived stress. Results may not be generalizable in a sample of highly stressed individuals who have experienced chronic dysregulation of their HPA axis affecting cortisol production. Third, data on exacerbations was self-reported, which is limited by poor recall. Fourth, the Life Events Checklist asks about life events that occurred anytime in the prior 12 months; however we did not have information on the timing of life events to determine if they were within the period that would reflect nail cortisol accumulation (3-5 months). Fifth, we did not have data on the presence of endocrine disorders which may have impacted cortisol levels. Finally, while our study excluded individuals who had an exacerbation in the prior month or were taking daily oral corticosteroids, it is unclear how treatment of exacerbations with oral corticosteroids in the preceding months (>1 month) may have affected nail cortisol levels. In addition, as inhaled corticosteroids (ICS) are widely used as part of triple therapy for COPD patients, this was not an exclusion criterion for our study and may have

influenced our results as ICS can suppress serum cortisol levels which may underestimate “stress” levels in an individual.³⁸ Regardless of these limitations, this is the first study to test the utility of nail cortisol in a sample of individuals with COPD and we provide a foundation upon which future studies can further investigate nail cortisol as a chronic stress biomarker.

In conclusion, in this cross-sectional study, nail cortisol was not a reliable marker of chronic stress in individuals living with COPD. Future research should examine the prospective relationship of perceived stress and nail cortisol, examine the utility of nail cortisol in a high stress population, and determine if nail cortisol is predictive of important clinical outcomes in COPD including exacerbations and cardiovascular events.

ACKNOWLEDGEMENTS

Disclosures: TMP is supported by the NHLBI (K23HL153672). J.M.W. served on an advisory board for GSK, Takeda, AstraZeneca, Bavarian Nordic, Krystal Biotech, Sanofi, and Verona Pharma; holds patent PCT/GB2021/050658 with Mereo BioPharma; received research support from Alpha-1 Foundation, ARCUS-Med, Department of Veteran Affairs, GlaxoSmithKline, Grifols, InhibrX, Medscape, Mereo BioPharma, NIH/NHLBI, Takeda, InhibrX, American Lung Association, and Verona Pharma; and holds stock in Alveolus Bio. MTD has received consulting fees from Aer Therapeutics, Aprea, AstraZeneca, Genentech, GSK, Novartis, Pulmonx, and Teva; received royalties from UptoDate; received travel support from GSK; received research support from the Department of Defense, American Lung Association, and NIH. ZH, EM, YK, RR, and DB have no disclosures.

Acknowledgements: We would like to acknowledge Melissa J. Sammy, PhD and Kelley E. Smith-Johnston, BS at the UAB Bio-Analytical Redox Biology (BARB) Core, DRC (NIDDK P30DK079626), Heersink School of Medicine, NORC (NIDDK P30DK056336) and CCTS (NIH UL1TR003096) for their assistance with measuring nail cortisol levels.

AUTHOR CONTRIBUTIONS

Conception and/or design of the study: TMP, MTD, JMW, YK

Acquisition of the data: TMP, MTD, JMW

Data analysis and/or interpretation: TMP, MTD, RR, YK, EM, DB, ZH

Writing the article and substantial involvement in its revision prior to submission: TMP, MTD, JMW, RR, YK, DB, EM, ZH

All authors have significantly contributed to the intellectual content of the article and gave final approval of this manuscript to be published.

Pre-proof

REFERENCES

1. Cohen S, Janicki-Deverts D, Miller GE. Psychological Stress and Disease. *JAMA*. 2007 Oct 10;298(14):1685–7.
2. Lu Y, Nyunt MSZ, Gwee X, Feng L, Feng L, Kua EH, et al. Life event stress and chronic obstructive pulmonary disease (COPD): associations with mental well-being and quality of life in a population-based study. *BMJ Open*. 2012;2(6).
3. Ge M, S C, Ak R. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association* [Internet]. 2002 Nov [cited 2024 Oct 14];21(6). Available from: <https://pubmed.ncbi.nlm.nih.gov/12433005/>
4. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. *PNAS*. 2012 Mar 27;201118355.
5. Parekh TM, Cherrington AL, Bhatia S, Turan B, Patel SB, Kim YI, et al. The Association of Low Income and High Stress with Acute Care Use in COPD Patients. *Chronic Obstr Pulm Dis*. 2020 Apr;7(2):107–17.
6. Duckworth AL, Quinn PD. Development and validation of the short grit scale (grit-s). *J Pers Assess*. 2009 Mar;91(2):166–74.
7. Knauff KM, Holt CA, Kalia V. Perceived Stress Mediates Associations Between Grit and Health-Related Quality of Life. *Psychol Rep*. 2024 Apr 18;332941241248607.
8. Dam A, Perera T, Jones M, Haughey M, Gaeta T. The Relationship Between Grit, Burnout, and Well-being in Emergency Medicine Residents. *AEM Educ Train*. 2019 Jan;3(1):14–9.
9. Andrés-Rodríguez L, Borràs X, Feliu-Soler A, Pérez-Aranda A, Rozadilla-Sacanell A, Montero-Marin J, et al. Immune-inflammatory pathways and clinical changes in fibromyalgia patients treated with Mindfulness-Based Stress Reduction (MBSR): A randomized, controlled clinical trial. *Brain Behav Immun*. 2019 Feb 25;
10. Wagner D, Pearcey SM. Perceived stress and salivary biomarkers in educators: comparison among three stress reduction activities. *Health Psychol Behav Med*. 2022;10(1):617–31.
11. Mendelson JH, Sholar MB, Goletiani N, Siegel AJ, Mello NK. Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. *Neuropsychopharmacology*. 2005 Sep;30(9):1751–63.
12. Schuetz P, Leuppi JD, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Prospective analysis of adrenal function in patients with acute exacerbations of COPD: the Reduction in the Use of Corticosteroids in Exacerbated COPD (REDUCE) trial. *European Journal of Endocrinology*. 2015 Jul 1;173(1):19–27.

13. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. *The Lancet*. 2000 Feb 12;355(9203):542–5.
14. Frugé AD, Cases MG, Howell CR, Tsuruta Y, Smith-Johnston K, Moellering DR, et al. Fingernail and toenail clippings as a non-invasive measure of chronic cortisol levels in adult cancer survivors. *Cancer Causes Control*. 2018 Jan;29(1):185–91.
15. Izawa S, Miki K, Tsuchiya M, Yamada H, Nagayama M. Hair and fingernail cortisol and the onset of acute coronary syndrome in the middle-aged and elderly men. *Psychoneuroendocrinology*. 2019 Mar;101:240–5.
16. 2024 GOLD Report [Internet]. Global Initiative for Chronic Obstructive Lung Disease - GOLD. [cited 2024 Sep 11]. Available from: <https://goldcopd.org/2024-gold-report/>
17. Warnock F, McElwee K, Seo RJ, McIsaac S, Seim D, Ramirez-Aponte T, et al. Measuring cortisol and DHEA in fingernails: a pilot study. *Neuropsychiatr Dis Treat*. 2010 Feb 3;6:1–7.
18. Meyer J, Novak M, Hamel A, Rosenberg K. Extraction and analysis of cortisol from human and monkey hair. *J Vis Exp*. 2014 Jan 24;(83):e50882.
19. Measuring cortisol and DHEA in fingernails: a pilot study. - PubMed - NCBI [Internet]. [cited 2019 Mar 20]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20169040>
20. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. *J Health Soc Behav*. 1983 Dec;24(4):385–96.
21. Cohen S. Perceived stress in a probability sample of the United States. In: *The social psychology of health*. Thousand Oaks, CA, US: Sage Publications, Inc; 1988. p. 31–67. (The Claremont Symposium on Applied Social Psychology).
22. Cohen S, Janicki-Deverts D. Who's Stressed? Distributions of Psychological Stress in the United States in Probability Samples from 1983, 2006, and 2009¹. *J Applied Social Psychol*. 2012 Jun;42(6):1320–34.
23. Cohen S, Tyrrell DA, Smith AP. Psychological stress and susceptibility to the common cold. *N Engl J Med*. 1991 Aug 29;325(9):606–12.
24. *Neurosis and the Social Environment* S. Henderson, D. G. Byrne, P. Duncan-Jones, Sydney: Academic Press, 1981, pp. 279, \$32.50. | Behavioural and Cognitive Psychotherapy | Cambridge Core [Internet]. [cited 2024 Oct 16]. Available from: <https://www.cambridge-org.uab.idm.oclc.org/core/journals/behavioural-and-cognitive-psychotherapy/article/abs/neurosis-and-the-social-environments-henderson-d-g-byrne-p-duncanjones-sydney-academic-press-1981-pp-279-3250/C051B0AC7A51A9608F54E56D0144CEAF>

25. Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care*. 2003 Nov;41(11):1284–92.
26. PRAPARE [Internet]. NACHC. [cited 2019 Sep 23]. Available from: <http://www.nachc.org/research-and-data/prapare/>
27. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. *Eur Respir J*. 2009 Sep;34(3):648–54.
28. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. *Chest*. 1988 Mar;93(3):580–6.
29. Izawa S, Matsudaira K, Miki K, Arisaka M, Tsuchiya M. Psychosocial correlates of cortisol levels in fingernails among middle-aged workers. *Stress*. 2017 Jul;20(4):386–9.
30. Schnall R, Liu J, Cordoba E, Brin M, Garofalo R, Kuhns LM, et al. Differences in Self-Reported Stress Versus. Hair and Nail Cortisol Among Adolescent and Young Adult Males. *Nurs Res*. 2024 Jul 17;
31. Doan SN, DeYoung G, Fuller-Rowell TE, Liu C, Meyer J. Investigating relations among stress, sleep and nail cortisol and DHEA. *Stress*. 2018 Mar 4;21(2):188–93.
32. Stalder T, Steudte-Schmiedgen S, Alexander N, Klucken T, Vater A, Wichmann S, et al. Stress-related and basic determinants of hair cortisol in humans: A meta-analysis. *Psychoneuroendocrinology*. 2017 Mar;77:261–74.
33. Jankovic-Rankovic J, Oka RC, Meyer JS, Gettler LT. Forced migration experiences, mental well-being, and nail cortisol among recently settled refugees in Serbia. *Soc Sci Med*. 2020 Aug;258:113070.
34. Davison B, Singh GR, Oguoma VM, McFarlane J. Fingernail cortisol as a marker of chronic stress exposure in Indigenous and non-Indigenous young adults. *Stress*. 2020 May;23(3):298–307.
35. Miller GE, Chen E, Zhou ES. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. *Psychological Bulletin*. 2007;133(1):25–45.
36. Elzinga BM, Roelofs K, Tollenaar MS, Bakvis P, van Pelt J, Spinhoven P. Diminished cortisol responses to psychosocial stress associated with lifetime adverse events: A study among healthy young subjects. *Psychoneuroendocrinology*. 2008 Feb 1;33(2):227–37.
37. Phillips R, Kraeuter AK, McDermott B, Lupien S, Sarnyai Z. Human nail cortisol as a retrospective biomarker of chronic stress: A systematic review. *Psychoneuroendocrinology*. 2021 Jan;123:104903.

38. Włodarczyk JH, Gibson PG, Caesar M. Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review. *Ann Allergy Asthma Immunol*. 2008 Jan;100(1):23–30.

Pre-proof

Table 1. Baseline Characteristics of Total Cohort

Variables	Total Sample (n=50)
Demographics	
Age, mean (SD)	64.53 (8.09)
Female sex, N (%)	21 (42)
Race, N(%)	
Non-Hispanic White	30 (60)
Black	18 (36)
Other	2 (4)
Smoking History, N(%)	
Never	2 (4)
Former	26 (52)
Current	22 (44)
Financial Insecurity, N(%)	7 (14)
Clinical Characteristics	
FEV1%, mean (SD)	49.72 (16.75)
FEV1, L, mean (SD)	1.38 (0.56)
FVC, L, mean (SD)	2.86 (0.8)
FEV1/FVC, mean (SD)	0.48 (0.12)
Severity of airflow obstruction n(%)	
FEV1% >80%	1 (2)
FEV1% 50-79%	21 (46)
FEV1% 30-49%	15 (33)
FEV1% <30%	8 (18)
Long-term Oxygen Therapy, N(%)	9 (19.15)
MMRC score, mean (SD)	1.88 (1.14)
Moderate AECOPD in the prior 12 months, mean (SD)	0.84 (1.28)
≥1 moderate AECOPD in the prior 12 months, n(%)	23 (46)
ED visit for AECOPD in the prior 12 months, mean (SD)	0.34 (0.96)
≥1 ED visit for AECOPD in the prior 12 months, n(%)	10 (20)
Hospitalization for AECOPD in the prior 12 months, mean (SD)	0.26 (0.72)
≥1 Hospitalization for AECOPD in the prior 12 months, n(%)	7 (14)
≥1 Severe exacerbation (ED or hospitalization) in the prior 12 months, n (%)	14 (28)
≥1 any exacerbations in the prior 12 months (moderate or severe) n (%)	24 (48)
CAT score, mean (SD)	19.68 (8.01)
Comorbidities, N(%)	
Coronary artery disease	11 (22)
Congestive heart failure	7 (14)
Stroke	4 (8)
Acid reflux	25 (50)
Anxiety	19 (38)
Depression	18 (36)
Hypertension	4 (8)
Osteoporosis	5 (10)
Sleep apnea	8 (16)
Lung cancer	1 (2)
Osteoarthritis	11 (22)
Health status, N(%)	
Excellent/Very good/Good	31 (62)
Fair/Poor	19 (38)
Stress-related Measurements	

Nail cortisol, nmol/g, mean (SD); median (IQR)	0.05 (0.09); 0.02 (0.03)
Serum cortisol, mcg/dl, mean (SD); median (IQR)	8.9 (4.11); 9.10 (5.3)
Fibrinogen, mg/dl, mean (SD) (n=49)	394.67 (87.51)
C-reactive protein, mg/L, mean (SD)	5 (5.58)
IL-1B, ng/ml, mean (SD) (n=46)	9.76 (28.54)
IL-6, ng/ml mean (SD) (n=46)	20.99 (66.14)
Perceived stress, mean (SD), median (IQR)	12.36 (5.91); 12 (9)
Grit score, mean (SD)	3.64 (0.62)
Total negative life events, mean (SD)	2.16 (2.21)
Social interactions with close friends, N (%)	
0-2x per week	10 (20)
3-5x per week	13 (26)
>5x per week	27 (54)
PHQ-2, mean (SD)	1.44 (1.75)
PHQ-2 score 3-6 (depression likely), N(%)	7 (14)

Abbreviations: AECOPD – acute exacerbation of COPD; CAT – COPD Assessment Test; IL-1B – interleukin 1 beta; IL-6 – interleukin 6MMRC – modified medical research council; Nmol/g – nanomole per gram; Ng/ml – nanogram per millimeter; PHQ-2 – Patient health questionnaire 2; SD – standard deviation.

Table 2. Correlation of Nail Cortisol with Serum Cortisol, Perceived Stress, and Inflammatory Biomarkers

	Nail Cortisol Pearson's Correlation (r), P-value
Perceived Stress	-0.11, p= 0.45
Serum Cortisol	0.04, p= 0.76
Fibrinogen	0.13, p = 0.38
IL-1B	-0.14, p =0.37
IL-6	-0.13, p = 0.37
C-reactive protein	-0.11, p = 0.47

Table 3. Stepwise Modeling Predicting Perceived Stress (n=46)

Variable	Unadjusted OR (95% Confidence interval)	P-value	AOR (95% Confidence interval)	P-value
Age	0.978 (0.911, 1.049)	0.5309	1.087 (0.94, 1.255)	0.2597
Male sex	0.282 (0.085, 0.938)	0.0390	0.369 (0.046, 2.935)	0.3458
White race vs other	1.833 (0.584, 5.758)	0.2992	0.766 (0.126, 4.649)	0.7721
Financial Instability	6.283 (0.697, 56.669)	0.1015	21.333 (0.601, 757.146)	0.0929
Fair/Poor Health Status vs Excellent/Very good/ Good	3.877 (1.116, 13.473)	0.0330	15.679 (1.6, 153.617)	0.0181
Grit Score	0.072 (0.015, 0.339)	0.0009	0.021 (0.002, 0.258)	0.0025

Table 4. Stepwise Modeling Predicting Serum Cortisol (n=46)

Variable	Unadjusted OR (95% Confidence interval)	P value	AOR (95% Confidence interval)	P-value
Age	1.032 (0.962, 1.108)	0.3809	1.014 (0.934, 1.101)	0.7361
Male sex	3.272 (1.008, 10.619)	0.0484	3.87 (0.924, 16.203)	0.0640
White race vs. other	0.716 (0.23, 2.23)	0.5642	0.916 (0.232, 3.611)	0.8999
Financial instability	0.716 (0.143, 3.589)	0.6845	0.968 (0.103, 9.091)	0.9770
Fibrinogen	1.01 (1.001, 1.018)	0.0216	1.009 (1.001, 1.017)	0.0375

Table 5. Stepwise Modeling Predicting Nail Cortisol (n=46)

Variable	Unadjusted OR (95% Confidence interval)	P-Value	AOR (95% Confidence interval)	P-value
Age	1.005 (0.938, 1.077)	0.8803	0.977 (0.894, 1.067)	0.6000
Male sex	1.641 (0.529, 5.093)	0.3913	1.746 (0.429, 7.1)	0.4362
White race vs. other	0.359 (0.111, 1.161)	0.0872	0.418 (0.103, 1.703)	0.2236
Financial instability	0.716 (0.143, 3.589)	0.6845	3.115 (0.347, 27.925)	0.3100
≥ 3 Total Negative Events	0.206 (0.055, 0.777)	0.0197	0.104 (0.017, 0.625)	0.0133

Online Supplement

Supplemental Table 1a. Baseline Characteristics of Low vs. High Perceived Stress (Median = 12)

Variables	Low Perceived Stress (<12)	High Perceived Stress (≥12)
Demographics		
Age, mean (SD)	65.30 (7.62)	63.87 (8.55)
Female sex, N (%)	6 (26.1)	15 (55.6)
Race, N(%)		
Non-Hispanic White	12 (52.2)	18 (66.7)
Black	9 (39.1)	9 (33.3)
Other	2 (8.7)	0 (0)
Smoking History, N(%)		
Never	2 (8.7)	0 (0)
Former	13 (56.5)	13 (48.1)
Current	8 (34.8)	14 (51.9)
Financial Insecurity, N(%)	1 (4.3)	6 (22.2)
Clinical Characteristics		
FEV1%, mean (SD)	49.46 (18.36)	49.97 (15.46)
FEV1, L, mean (SD)	1.43 (0.61)	1.34 (0.52)
FVC, L, mean (SD)	3.07 (0.91)	2.67 (0.66)
FEV1/FVC, mean (SD)	0.46 (0.12)	0.50 (0.13)
Severity of airflow obstruction n(%)		
FEV1% >80%	1 (4.5)	0 (0)
FEV1% 50-79%	10 (45.5)	11 (47.8)
FEV1% 30-49%	6 (27.3)	9 (39.1)
FEV1% <30%	5 (22.7)	3 (13)
Long-term Oxygen Therapy, N(%)	6 (27.3)	3 (12)
MMRC score, mean (SD)	2.00 (1.17)	1.78 (1.12)
Moderate AECOPD in the prior 12 months, mean (SD)	0.70 (1.06)	0.96 (1.45)
≥1 moderate AECOPD in the prior 12 months, n(%)	10 (43.5)	13 (48.1)
ED visit for AECOPD in the prior 12 months, mean (SD)	0.26 (0.54)	0.41 (1.22)
≥1 ED visit for AECOPD in the prior 12 months, n(%)	5 (21.7)	5 (18.5)
Hospitalization for AECOPD in the prior 12 months, mean (SD)	0.04 (0.21)	0.44 (0.93)
≥1 Hospitalization for AECOPD in the prior 12 months, n(%)	1 (4.3)	6 (22.2)
≥1 Severe exacerbation (ED or hospitalization) in the prior 12 months, n (%)	5 (21.7)	9 (33.3)
≥1 any exacerbations in the prior 12 months (moderate or severe) n (%)	10 (43.5)	14 (51.9)
CAT score, mean (SD)	16.09 (6.36)	22.74 (8.10)
Comorbidities, N(%)		
Coronary artery disease	6 (26.1)	5 (18.5)
Congestive heart failure	4 (17.4)	3 (11.1)
Stroke	3 (13)	1 (3.7)

Acid reflux	12 (52.2)	13 (48.1)
Anxiety	6 (26.1)	13 (48.1)
Depression	5 (21.7)	13 (48.1)
Hypertension	3 (13)	1 (3.7)
Osteoporosis	2 (8.7)	3 (11.1)
Sleep apnea	3 (13)	5 (18.5)
Lung cancer	1 (4.3)	0 (0)
Osteoarthritis	6 (26.1)	5 (18.5)
Health status, N(%)		
Excellent/Very good/Good	18 (78.3)	13 (48.1)
Fair/Poor	5 (21.7)	14 (51.9)
Stress-related Measurements		
Nail cortisol, nmol/g, mean (SD); median (IQR)	0.06 (0.11)	0.05 (0.08)
Serum cortisol, mcg/dl, mean (SD); median (IQR)	9.74 (4.68)	8.19 (3.49)
Fibrinogen, mg/dl, mean (SD) (n=49)	397.41 (96.65)	392.44 (81.13)
C-reactive protein, mg/L, mean (SD)	5.21 (6.37)	4.82 (4.93)
IL-1B, ng/ml, mean (SD) (n=46)	8.14 (28.44)	11.13 (29.14)
IL-6, ng/ml mean (SD) (n=46)	18.91 (68.67)	22.74 (65.31)
Grit score, mean (SD)	4.00 (0.40)	3.32 (0.60)
Total negative life events, mean (SD)	1.13 (1.29)	3.04 (2.46)
Social interactions with close friends, N (%)		
0-2x per week	4 (17.4)	6 (22.2)
3-5x per week	7 (30.4)	6 (22.2)
>5x per week	12 (52.2)	15 (55.6)
PHQ-2, mean (SD)	0.74 (1.21)	2.04 (1.93)
PHQ-2 score 3-6 (depression likely), N(%)	1 (4.3)	6 (22.2)

Abbreviations: AECOPD – acute exacerbation of COPD; CAT – COPD Assessment Test; IL-1B – interleukin 1 beta; IL-6 – interleukin 6; MMRC – modified medical research council; Nmol/g – nanomole per gram; Ng/ml – nanogram per millimeter; PHQ-2 – Patient health questionnaire 2; SD – standard deviation.

*Bold font indicates p value <0.05 for differences between high and low groups

Supplemental Table 1b. Baseline Characteristics of Low vs. High Serum Cortisol (Median 9.1 mcg/dl)

Variables	Low Serum Cortisol (<9.1)	High Serum Cortisol (≥9.1)
Demographics		
Age, mean (SD)	63.53 (7.38)	65.53 (8.77)
Female sex, N (%)	14 (56)	7 (28)
Race, N(%)		
Non-Hispanic White	16 (64)	14 (56)
Black	9 (36)	9 (36)
Other	0 (0)	2 (8)
Smoking History, N(%)		
Never	0 (0)	2 (8)
Former	13 (52)	13 (52)
Current	12 (48)	10 (40)
Financial Insecurity, N(%)	4 (16)	3 (12)
Clinical Characteristics		
FEV1%, mean (SD)	47.89 (15.57)	51.64 (18.06)
FEV1, L, mean (SD)	1.27 (0.49)	1.51 (0.61)
FVC, L, mean (SD)	2.76 (0.73)	2.97 (0.88)
FEV1/FVC, mean (SD)	0.46 (0.13)	0.50 (0.12)
Severity of airflow obstruction n(%)		
FEV1% >80%	0 (0)	1 (4.5)
FEV1% 50-79%	10 (43.5)	11 (50)
FEV1% 30-49%	9 (39.1)	6 (27.3)
FEV1% <30%	4 (17.4)	4 (18.2)
Long-term Oxygen Therapy, N(%)	5 (20)	4 (18.2)
MMRC score, mean (SD)	1.68 (1.07)	2.08 (1.19)
Moderate AECOPD in the prior 12 months, mean (SD)	0.92 (1.26)	0.76 (1.33)
≥1 moderate AECOPD in the prior 12 months, n(%)	12 (48)	11 (44)
ED visit for AECOPD in the prior 12 months, mean (SD)	0.52 (1.29)	0.16 (0.37)
≥1 ED visit for AECOPD in the prior 12 months, n(%)	6 (24)	4 (16)
Hospitalization for AECOPD in the prior 12 months, mean (SD)	0.36 (0.91)	0.16 (0.47)
≥1 Hospitalization for AECOPD in the prior 12 months, n(%)	4 (16)	3 (12)
≥1 Severe exacerbation (ED or hospitalization) in the prior 12 months, n (%)	8 (32)	6 (24)
≥1 any exacerbations in the prior 12 months (moderate or severe) n (%)	13 (52)	11 (44)
CAT score, mean (SD)	21.16 (7.49)	18.20 (8.39)
Comorbidities, N(%)		
Coronary artery disease	2 (8)	9 (36)
Congestive heart failure	3 (12)	4 (16)
Stroke	2 (8)	2 (8)
Acid reflux	12 (48)	13 (52)

Anxiety	12 (48)	7 (28)
Depression	11 (44)	7 (28)
Hypertension	1 (4)	3 (12)
Osteoporosis	2 (8)	3 (12)
Sleep apnea	1 (4)	7 (28)
Lung cancer	1 (4)	0 (0)
Osteoarthritis	4 (16)	7 (28)
Health status, N(%)		
Excellent/Very good/Good	18 (72)	13 (52)
Fair/Poor	7 (28)	12 (48)
Stress-related Measurements		
Nail cortisol, nmol/g, mean (SD); median (IQR)	0.05 (0.10)	0.05 (0.09)
Fibrinogen, mg/dl, mean (SD) (n=49)	364.68 (73.61)	425.92 (91.28)
C-reactive protein, mg/L, mean (SD)	4.43 (4.96)	5.57 (6.19)
IL-1B, ng/ml, mean (SD) (n=46)	8.03 (27.19)	11.35 (30.22)
IL-6, ng/ml mean (SD) (n=46)	24.08 (69.45)	18.16 (64.33)
Perceived stress, mean (SD), median (IQR)	13.84 (6.09)	10.88 (5.45)
Grit score, mean (SD)	3.43 (0.56)	3.85 (0.61)
Total negative life events, mean (SD)	2.60 (2.55)	1.72 (1.74)
Social interactions with close friends, N (%)		
0-2x per week	3 (12)	7 (28)
3-5x per week	5 (20)	8 (32)
>5x per week	17 (68)	10 (40)
PHQ-2, mean (SD)	1.84 (1.91)	1.04 (1.51)
PHQ-2 score 3-6 (depression likely), N(%)	6 (24)	1 (4)

Abbreviations: AECOPD – acute exacerbation of COPD; CAT – COPD Assessment Test; IL-1B – interleukin 1 beta; IL-6 – interleukin 6; MMRC – modified medical research council; Nmol/g – nanomole per gram; Ng/ml – nanogram per milliliter; PHQ-2 – Patient health questionnaire 2; SD – standard deviation.

*Bold font indicates p value <0.05 for differences between high and low groups

Supplemental Table 1c. Baseline Characteristics of Low vs. High Nail Cortisol (Median = 0.016 nmol/g)

Variables	Low Nail Cortisol (<0.016)	High Nail Cortisol (≥0.016)
Demographics		
Age, mean (SD)	64.36 (6.83)	64.70 (9.32)
Female sex, N (%)	12 (48)	9 (36)
Race, N(%)		
Non-Hispanic White	18 (72)	12 (48)
Black	6 (24)	12 (48)
Other	1 (4)	1 (4)
Smoking History, N(%)		
Never	2 (8)	0 (0)
Former	11 (44)	15 (60)
Current	12 (48)	10 (40)
Financial Insecurity, N(%)	4 (16)	3 (12)
Clinical Characteristics		
FEV1%, mean (SD)	45.35 (17.26)	54.30 (15.25)
FEV1, L, mean (SD)	1.30 (0.58)	1.48 (0.53)
FVC, L, mean (SD)	2.84 (0.94)	2.87 (0.63)
FEV1/FVC, mean (SD)	0.45 (0.12)	0.51 (0.13)
Severity of airflow obstruction n(%)		
FEV1% >80%	0 (0)	1 (4.5)
FEV1% 50-79%	9 (39.1)	12 (54.5)
FEV1% 30-49%	7 (30.4)	8 (36.4)
FEV1% <30%	7 (30.4)	1 (4.5)
Long-term Oxygen Therapy, N(%)	5 (21.7)	4 (16.7)
MMRC score, mean (SD)	1.72 (1.14)	2.04 (1.14)
Moderate AECOPD in the prior 12 months, mean (SD)	1.24 (1.56)	0.44 (0.77)
≥1 moderate AECOPD in the prior 12 months, n(%)	15 (60)	8 (32)
ED visit for AECOPD in the prior 12 months, mean (SD)	0.60 (1.29)	0.08 (0.28)
≥1 ED visit for AECOPD in the prior 12 months, n(%)	8 (32)	2 (8)
Hospitalization for AECOPD in the prior 12 months, mean (SD)	0.44 (0.96)	0.08 (0.28)
≥1 Hospitalization for AECOPD in the prior 12 months, n(%)	5 (20)	2 (8)
≥1 Severe exacerbation (ED or hospitalization) in the prior 12 months, n (%)	10 (40)	4 (16)
≥1 any exacerbations in the prior 12 months (moderate or severe) n (%)	16 (64)	8 (32)
CAT score, mean (SD)	19.84 (6.72)	19.52 (9.27)
Comorbidities, N(%)		
Coronary artery disease	6 (24)	5 (20)
Congestive heart failure	4 (16)	3 (12)
Stroke	3 (12)	1 (4)
Acid reflux	16 (64)	9 (36)

Anxiety	11 (44)	8 (32)
Depression	9 (36)	9 (36)
Hypertension	0 (0)	4 (16)
Osteoporosis	4 (16)	1 (4)
Sleep apnea	5 (20)	3 (12)
Lung cancer	0 (0)	1 (4)
Osteoarthritis	2 (8)	9 (36)
Health status, N(%)		
Excellent/Very good/Good	17 (68)	14 (56)
Fair/Poor	8 (32)	11 (44)
Stress-related Measurements		
Serum cortisol, mcg/dl, mean (SD); median (IQR)	8.08 (4.55)	9.72 (3.52)
Fibrinogen, mg/dl, mean (SD) (n=49)	378.40 (86.69)	411.63 (86.91)
C-reactive protein, mg/L, mean (SD)	4.49 (4.57)	5.51 (6.50)
IL-1B, ng/ml, mean (SD) (n=46)	7.35 (17.62)	11.98 (36.05)
IL-6, ng/ml mean (SD) (n=46)	22.07 (68.84)	20.00 (65.03)
Perceived stress, mean (SD), median (IQR)	12.60 (6.04)	12.12 (5.90)
Grit score, mean (SD)	3.57 (0.52)	3.71 (0.71)
Total negative life events, mean (SD)	2.52 (1.94)	1.80 (2.43)
Social interactions with close friends, N (%)		
0-2x per week	8 (32)	2 (8)
3-5x per week	7 (28)	6 (24)
>5x per week	10 (40)	17 (68)
PHQ-2, mean (SD)	1.64 (1.73)	1.24 (1.79)
PHQ-2 score 3-6 (depression likely), N(%)	3 (12)	4 (16)

Abbreviations: AECOPD – acute exacerbation of COPD; CAT – COPD Assessment Test; IL-1B – interleukin 1 beta; IL-6 – interleukin 6; MMRC – modified medical research council; Nmol/g – nanomole per gram; Ng/ml – nanogram per millimeter; PHQ-2 – Patient health questionnaire 2; SD – standard deviation.

*Bold font indicates p value <0.05 for differences between high and low groups

Supplemental Table 2. Univariate Analysis of Serum Cortisol (continuous), Nail cortisol (continuous) and Perceived Stress (continuous) with Co-variables of Interest

	Perceived Stress		Serum Cortisol		Nail Cortisol	
	Beta (SE)	P value	Beta (SE)	P value	Beta (SE)	P value
Age	-0.0567 (0.105)	0.5924	0.0551 (0.073)	0.4535	0.001 (0.002)	0.5590
Male Sex	-4.4696 (1.586)	0.0069	1.4374 (1.172)	0.2261	0.0122 (0.027)	0.6519
White Race vs Other	2.9333 (1.672)	0.0857	-1.4363 (1.181)	0.2299	-0.0407 (0.026)	0.1305
Current Smoking Status	1.3864 (1.69)	0.4162	-0.2849 (1.183)	0.8106	-0.0184 (0.027)	0.4936
≥1 Moderate Exacerbations vs none	0.2995 (1.695)	0.8604	-0.6211 (1.175)	0.5996	0.0089 (0.027)	0.7394
≥1 ED Exacerbations vs none	0.175 (2.112)	0.9343	-1.3165 (1.457)	0.3705	-0.0208 (0.033)	0.5325
≥1 Hospitalized Exacerbations vs none	4.2326 (2.357)	0.0788	-1.3492 (1.682)	0.4264	-0.0296 (0.038)	0.4393
FEV1 % predicted	-0.0076 (0.054)	0.8888	0.0384 (0.038)	0.3190	-0.0001 (0.001)	0.9053
FEV1 L	-1.0797 (1.585)	0.4992	1.5359 (1.108)	0.1726	-0.0302 (0.024)	0.2094
FVC L	-1.5471 (1.108)	0.1696	0.3642 (0.803)	0.6524	-0.0208 (0.017)	0.2247
FEV1/FVC ratio	4.1328 (7.14)	0.5656	7.3298 (4.971)	0.1474	-0.0435 (0.108)	0.6905
CAT score	0.3659 (0.093)	0.0002	-0.0703 (0.073)	0.3425	-0.0007 (0.002)	0.6905
MMRC	0.2712 (0.75)	0.7192	0.4987 (0.517)	0.3398	0.0153 (0.012)	0.1923
PHQ2	1.81 (0.411)	<0.0001	-0.4531 (0.332)	0.1793	-0.0055 (0.008)	0.4772
Grit	-5.1214 (1.168)	<0.0001	1.4969 (0.937)	0.1165	0.0154 (0.022)	0.4794
Health status (poor, fair vs Excellent/very good/good)	3.1545 (1.68)	0.0665	-0.2938 (1.21)	0.8091	0.0006 (0.027)	0.9823
Fibrinogen	-0.0009 (0.01)	0.9286	0.0131 (0.007)	0.0517	0.0001 (0.0002)	0.3802
CRP	-0.022 (0.153)	0.8859	0.059 (0.106)	0.5803	-0.0017 (0.002)	0.4677
IL-1b	0.0272 (0.029)	0.3524	0.0129 (0.02)	0.5235	-0.0005 (0.001)	0.3705
IL-6	0.0002 (0.013)	0.9867	0.0074 (0.009)	0.3962	-0.0002 (0.0002)	0.3731
Income						
Tertile1 (<= 12,200) vs Tertile3 (> 24,000)	3 (2.303)	0.2013	1.5333 (1.646)	0.3582	0.0401 (0.036)	0.2774
Tertile2 (>12,200-24,000) vs Tertile3(> 24,000)	-0.6026 (2.258)	0.7911	1.3931 (1.614)	0.3942	0.0718 (0.036)	0.0515
Financial insecurity Yes vs No	5.5615 (2.299)	0.0194	-0.3027 (1.693)	0.8588	-0.001 (0.038)	0.9786
Social interactions with close friends						
0-2x/week vs ≥5x/ week	2.1481 (2.213)	0.3365	1.4927 (1.509)	0.3277	-0.0492 (0.034)	0.1523
3-5x/week vs ≥5x/ week	0.302 (2.018)	0.8816	2.1974 (1.376)	0.1170	-0.0498 (0.031)	0.1132
Total negative events	1.2488 (0.342)	0.0006	-0.1782 (0.268)	0.5087	-0.0119 (0.006)	0.0467

Beta coefficient (standard error) from regression models(glm) provided

Supplemental Figure 1

